|
|
|
European Biopharmaceutical Review
|
|
The economic crisis sweeping around the world has affected many industries, leaving few unscathed, and biotech companies have been no exception. Current market value does not seem to depend on the real worth of these companies or their technology, with many biotechs losing significant value on the markets seemingly overnight. In contrast, it is the cash-rich big pharma companies who are among the best positioned during these uncertain times, and who could also prove to be the saviours for many biotechs otherwise heading for failure. The concept of risk has changed for big pharma and it is time to nourish empty pipelines and start buying, with the multibillion dollar acquisitions of Wyeth by Pfizer and Schering- Plough by Merck recent examples of big buys. However, what exactly is the risk? |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Before co-founding Bionest in 2003, Alain J Gilbert was European Founding President of Biogen Inc (BGEN), where he was responsible for the launch of Avonex®, a biotech breakthrough treatment for MS. He held several positions at senior management level, such as European founder of IDEXX Labs Inc (IDXX) and President of Medtronic Europe. Alain started his career in sales and marketing at Abbott’s Diagnostic Division and remained there for 17 years, holding key executive positions in the US and Europe. At Bionest, Alain is involved in biopharmaceutical, animal health, product launch, private equity and is focused on the US.
Dr Meredith Edwards joined Bionest in 2007 as a consultant. She obtained her medical degree in Australia. Before joining Bionest, Meredith worked as a Doctor for over two years in Australia and the UK. She was then appointed to Medical Affairs Director in a Clinical Research Organisation (CRO) in Paris. Since joining Bionest, she has participated in major ex-US operational product launch plans, regulatory strategy projects and has authored several articles in industry magazines. Her main focus is on biopharmaceutical companies in the US and European markets. |
|
|
|
|
|
 |
Industry Events |
 |
Paediatric Clinical Trials
21-22 March 2012, Copthorne Tara Hotel, London, United Kingdom
Designing accurate and safe paediatric formulations is one of the topics being discussed at SMi’s Paediatric Clinical Trials held on 21st & 22nd March 2012
More info >> |
|
 |
News and Press Releases |
 |
AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.
More info >> |
|
|
